Limits...
Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis.

Castellucci LA, Le Gal G, Rodger MA, Carrier M - J. Thromb. Haemost. (2014)

Bottom Line: The risk of major bleeding in patients who have completed anticoagulation therapy for unprovoked venous thromboembolism (VTE) is unknown.We used a random-effects model to pool study results and I(2) testing to assess for heterogeneity.The analysis included 11 studies and 3965 patients who were followed for a median of 24 months.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, The Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, ON, Canada.

Show MeSH

Related in: MedlinePlus

Forest plot of pooled proportions of major bleeding rates in patients randomized to placebo, observation, and overall (per 100 patient-years).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4230389&req=5

fig01: Forest plot of pooled proportions of major bleeding rates in patients randomized to placebo, observation, and overall (per 100 patient-years).

Mentions: The overall pooled major bleeding rate in patients who have completed anticoagulation for the secondary prevention of recurrent VTE (i.e. no longer on anticoagulant therapy) was 0.45 per 100 patient-years (95% CI 0.29–0.64, I2 = 0%). The pooled major bleeding rate for patients randomized to placebo was 0.42 per 100 patient-years (95% CI 0.25–0.62, I2 = 0%), and that for patients randomized to observation was 0.62 per 100 patient-years (95% CI 0.23–1.2, I2 = 0%) (Fig.1). Fatal bleeding events were rare with an overall pooled fatal bleeding rate of 0.14 per 100 patient-years (95% CI 0.057–0.26, I2 = 0%). In the studies reporting sites of major bleeding and fatal bleeding, intracranial hemorrhage (including subdural and subarachnoid bleeding) and gastrointestinal bleeding were most common.


Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis.

Castellucci LA, Le Gal G, Rodger MA, Carrier M - J. Thromb. Haemost. (2014)

Forest plot of pooled proportions of major bleeding rates in patients randomized to placebo, observation, and overall (per 100 patient-years).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4230389&req=5

fig01: Forest plot of pooled proportions of major bleeding rates in patients randomized to placebo, observation, and overall (per 100 patient-years).
Mentions: The overall pooled major bleeding rate in patients who have completed anticoagulation for the secondary prevention of recurrent VTE (i.e. no longer on anticoagulant therapy) was 0.45 per 100 patient-years (95% CI 0.29–0.64, I2 = 0%). The pooled major bleeding rate for patients randomized to placebo was 0.42 per 100 patient-years (95% CI 0.25–0.62, I2 = 0%), and that for patients randomized to observation was 0.62 per 100 patient-years (95% CI 0.23–1.2, I2 = 0%) (Fig.1). Fatal bleeding events were rare with an overall pooled fatal bleeding rate of 0.14 per 100 patient-years (95% CI 0.057–0.26, I2 = 0%). In the studies reporting sites of major bleeding and fatal bleeding, intracranial hemorrhage (including subdural and subarachnoid bleeding) and gastrointestinal bleeding were most common.

Bottom Line: The risk of major bleeding in patients who have completed anticoagulation therapy for unprovoked venous thromboembolism (VTE) is unknown.We used a random-effects model to pool study results and I(2) testing to assess for heterogeneity.The analysis included 11 studies and 3965 patients who were followed for a median of 24 months.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, The Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, ON, Canada.

Show MeSH
Related in: MedlinePlus